prabotulinumtoxina

Contraindicated in:

Hypersensitivity to botulinum toxin products or additives;
Infection at injection site.

Use Cautiously in:

Previous surgical facial alterations, marked facial asymmetry, ptosis, known weakness/atrophy of muscle in question, or inflammation/skin abnormality at injection site;
Atrophy of muscle in question or inflammation or skin abnormality at injection site;
Cardiovascular disease;
Peripheral motor neuropathic disorders (may exacerbate clinical effects and ↑ the risk of severe dysphagia and respiratory compromise);
Swallowing or breathing difficulties (may exacerbate underlying condition);
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: MI, ARRHYTHMIA

EENT: blurred vision, diplopia, drooping eyelid, dry eye, dysphonia

GI: dysphagia

GU: urinary incontinence

MS: muscle weakness

Neuro: headache, dysarthria

Resp: dyspnea

Misc: hypersensitivity reactions (including anaphylaxis), SPREAD OF TOXIN EFFECT

Interactions ⬆ ⬇

Drug-drug:

Concurrent use of aminoglycosides or other agents interfering with neuromuscular transmission, including muscle relaxants, may ↑ effect.
Concurrent use of anticholinergics may ↑ systemic anticholinergic effects.

Availability ⬆ ⬇

Lyophilized powder for injection: 100 units/vial

Route/Dosage ⬆ ⬇

PrabotulinumtoxinA is not interchangeable with other botulinum toxin products.

IM (Adults ): 20 units, divided in five equal aliquots of 4 units; may be repeated every 3 mo.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits release of acetylcholine from peripheral cholinergic nerve endings, resulting in chemical denervation of treated muscle.

Therapeutic effects:

Decreased appearance of glabellar lines.

Classifications ⬆ ⬇

Therapeutic Classification: cosmetic agents

Pharmacologic Classification: neurotoxins

Pharmacokinetics ⬆ ⬇

Absorption: Minimal systemic absorption.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(improvement in appearance of glabellar lines)

ROUTE	ONSET	PEAK	DURATION
IM	within 4 wk	unknown	up to 3 mo

Patient/Family Teaching ⬆ ⬇

Explain purpose and effects of Jeuveau to patient.
Advise patient to inform health care professional if any unusual symptoms (including difficulty with swallowing, speaking or breathing) occur, or if any known symptom persists or worsens.
May cause loss of strength, muscle weakness, blurred vision, or drooping eyelids. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Inform patients Jeuveau may cause eye dryness. Advise patient to notify health care professional if symptoms of eye dryness (eye pain, eye irritation, photosensitivity, changes in vision) occur.
Inform patient that injection may to spread from injection site to distant parts of the body. May occur within hrs or several wks after injection. Advise patient to notify health care professional immediately if swallowing, speech, or respiratory disorders arise.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇